FDA raises penalties for violators; Roche demolishes most of its vacated NJ campus; India's DCGI restores Ranbaxy export license;

> The FDA raised its penalties for companies found violating FDA regulations. Story

> The U.S. Generic Pharmaceutical Association (GPhA) has joined the "Stop the Fakes" global campaign against counterfeit medicine. Announcement

> The Drug Controller General of India has restored the export license to Ranbaxy Laboratories' Toansa plant after European regulators lifted a ban for the plant. Story

> Field testing has begun in Ghana, Africa, on the device the FDA developed for testing for counterfeit and substandard drugs. Report

> ScinoPharm Taiwan is developing and will produce the active pharmaceutical ingredients Burixafor, a new chemical entity discovered and developed by Taiwan-based TaiGen Biotechnology. Release

> The Drug Supply Chain Security Act does not require drugmakers to supply aggregation data to their trading partners before 2023. Blog Post

> U.K.-based Cherwell Laboratories, which makes Redipor prepared microbiological media, has completed an expansion of its manufacturing facility. Report

And Finally... Roche ($RHHBY) is demolishing all but 5 of the 40 buildings on its former R&D campus in New Jersey and expects to sell the property to a single developer by the end of the year. Story

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.